<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumor</z:e> invasion marks a critical point in <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">cancer progression</z:e>; it is a harbinger of morbidity and mortality </plain></SENT>
<SENT sid="1" pm="."><plain>Thus, the cellular events that enable the invasive phenotype are under intense investigation </plain></SENT>
<SENT sid="2" pm="."><plain>Epstein-Barr virus (EBV) is associated with a number of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e>, including Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) and nasopharyngeal <z:mp ids='MP_0002038'>carcinoma</z:mp> (NPC) and is suspected to contribute to their <z:mp ids='MP_0002006'>tumorigenesis</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>On average, 8% of gastric <z:mp ids='MP_0002038'>carcinomas</z:mp> have been shown to carry this virus </plain></SENT>
<SENT sid="4" pm="."><plain>To explore whether the presence of EBV in gastric <z:mp ids='MP_0002038'>carcinoma</z:mp> contributes to <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">tumor progression</z:e> in this predominantly invasive <z:mp ids='MP_0002038'>carcinoma</z:mp>, we examined a panel of 2 in vitro EBV-infected human <z:hpo ids='HP_0012126'>gastric cancer</z:hpo> cell line sublines and their mock-infected <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AGS</z:e> parental control line </plain></SENT>
<SENT sid="5" pm="."><plain>We found <z:e sem="disease" ids="C0149678" disease_type="Disease or Syndrome" abbrv="">EBV infection</z:e> caused a marked increase in transmigration of a Matrigel barrier (415% and 303%, p &lt; 0.05, for the 2 infected lines) </plain></SENT>
<SENT sid="6" pm="."><plain>This correlated with increased motility of these sublines (233% and 140%, p &lt; 0.05) </plain></SENT>
<SENT sid="7" pm="."><plain>As this pattern of increased motility leading to a more pronounced enhancement of invasion has been noted in other <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells, we explored the roles of autocrine signaling pathways previously implicated in <z:mp ids='MP_0002038'>carcinoma</z:mp> motility and invasion </plain></SENT>
<SENT sid="8" pm="."><plain>Inhibitors to the epidermal growth factor receptor (EGFR) (PD153035), phospholipase C (PLC) (U73122), extracellular-signal regulated kinase (ERK)/<z:chebi fb="0" ids="52290">mitogen</z:chebi>-activated protein kinase (MAPK) (PD089035) and PI-3 kinase (<z:chebi fb="0" ids="52289">Wortmannin</z:chebi>) were not informative </plain></SENT>
<SENT sid="9" pm="."><plain>These data suggest that EBV increases migration of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AGS</z:e> cells by a mechanism independent of these autocrine growth factor-induced pathways </plain></SENT>
<SENT sid="10" pm="."><plain>Instead, we found that the EBV-infected cells presented increased focal <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> kinase (FAK) phosphorylation </plain></SENT>
<SENT sid="11" pm="."><plain>These findings suggest a role for integrin-mediated signaling in promoting EBV-associated invasiveness </plain></SENT>
</text></document>